JP2020502106A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502106A5
JP2020502106A5 JP2019531623A JP2019531623A JP2020502106A5 JP 2020502106 A5 JP2020502106 A5 JP 2020502106A5 JP 2019531623 A JP2019531623 A JP 2019531623A JP 2019531623 A JP2019531623 A JP 2019531623A JP 2020502106 A5 JP2020502106 A5 JP 2020502106A5
Authority
JP
Japan
Prior art keywords
bipolar disorder
pharmaceutical composition
formula
group
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531623A
Other languages
English (en)
Japanese (ja)
Other versions
JP7208139B2 (ja
JP2020502106A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2017/014740 external-priority patent/WO2018111008A1/ko
Publication of JP2020502106A publication Critical patent/JP2020502106A/ja
Publication of JP2020502106A5 publication Critical patent/JP2020502106A5/ja
Application granted granted Critical
Publication of JP7208139B2 publication Critical patent/JP7208139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531623A 2016-12-14 2017-12-14 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 Active JP7208139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
KR10-2016-0170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2020502106A JP2020502106A (ja) 2020-01-23
JP2020502106A5 true JP2020502106A5 (https=) 2021-01-14
JP7208139B2 JP7208139B2 (ja) 2023-01-18

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531623A Active JP7208139B2 (ja) 2016-12-14 2017-12-14 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用

Country Status (14)

Country Link
US (1) US11571410B2 (https=)
EP (1) EP3556366B1 (https=)
JP (1) JP7208139B2 (https=)
KR (1) KR102635938B1 (https=)
CN (1) CN110290788A (https=)
AU (1) AU2017374458B2 (https=)
BR (1) BR112019011930A2 (https=)
CL (1) CL2019001618A1 (https=)
ES (1) ES3054693T3 (https=)
IL (1) IL267195B2 (https=)
MX (1) MX2019006940A (https=)
MY (1) MY199104A (https=)
WO (1) WO2018111008A1 (https=)
ZA (1) ZA201903747B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3854392A4 (en) * 2018-09-21 2022-08-17 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO PREVENT, RELIEVE OR TREAT CONJUNCTING SEIGES
ES2978226T3 (es) * 2018-09-21 2024-09-09 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático
BR112022009533A2 (pt) * 2019-11-22 2022-08-02 Sk Biopharmaceuticals Co Ltd Composição farmacêutica para administração oral, e, método para preparar uma composição farmacêutica

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL192029B1 (pl) * 1997-08-14 2006-08-31 Hoffmann La Roche Zastosowanie heterocyklicznych eterów winylowych, nowe heterocykliczne etery winylowe, sposób ich wytwarzania i środek farmaceutyczny
CN1251758C (zh) 2000-07-21 2006-04-19 特瓦制药工业有限公司 丙戊酸和2-丙基戊烯酸酰胺的衍生物在制备治疗双极情感障碍症躁狂病药物中的用途
US7122576B2 (en) * 2001-02-27 2006-10-17 Plata-Salaman Carlos R Carbamate compounds for use in preventing or treating bipolar disorder
ES2262801T3 (es) * 2001-02-27 2006-12-01 Ortho-Mcneil Pharmaceutical, Inc. Uso de un compuesto de carbamato para la prevencion o el tratamiento de trastorno bipolar.
AU2005307797B2 (en) 2004-11-16 2011-06-02 Alkermes Pharma Ireland Limited Injectable nanoparticulate olanzapine formulations
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
BRPI0718323A2 (pt) * 2006-10-31 2013-11-26 Janssen Pharmaceutica Nv Tratamento de transtornos invasivos do desenvolvimento.
WO2010150946A1 (en) 2009-06-22 2010-12-29 Sk Holdings Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
WO2016025917A1 (en) * 2014-08-15 2016-02-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors

Similar Documents

Publication Publication Date Title
JP2016512531A5 (https=)
JP2019524883A5 (https=)
JP2016518437A5 (https=)
RU2015143610A (ru) Лечение катаплексии
JP2017527532A5 (https=)
JP2015532295A5 (https=)
JP2009541223A5 (https=)
JP2016040288A5 (https=)
JP2017511360A5 (https=)
JP2014511891A5 (https=)
JP2019516739A5 (https=)
JP2018517686A5 (https=)
JP2015511609A5 (https=)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2017510610A5 (https=)
JP2019535723A5 (https=)
JP2019505529A5 (https=)
RU2018113718A (ru) Новые соединения
JP2019520344A5 (https=)
JP2011509302A5 (https=)
JP2021504384A5 (https=)
JP2020502106A5 (https=)
RU2011147186A (ru) 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3
JP2011518168A5 (https=)
JP2019516726A5 (https=)